Epidermal growth factor receptor-targeted agents and paronychia: A US Food and Drug Administration Adverse Event Reporting System–based real-world pharmacovigilance analysis - 18/06/26
Doi : 10.1016/j.jaad.2026.03.031
Siqi Sun, MD a, Hongfeng Mao, MD b, Yihe Yu, MD a, Jintao Ning, MD a, Yunlei Pan, PhD c, ⁎ 
, Hongyu Jia, PhD a, ⁎
, Hongyu Jia, PhD a, ⁎ a State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou Zhejiang, China
b Department of Endocrinology and Metabolism, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
c Department of Dermatology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
∗ Correspondence to: Hongyu Jia, PhD, Department of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou Zhejiang, China Department of Infectious Diseases First Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China ∗∗ Yunlei Pan, PhD, Department of Dermatology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China Department of Dermatology the First Affiliated Hospital College of Medicine Zhejiang University Hangzhou China
Key words : dermatologic adverse events, epidermal growth factor receptor inhibitors (EGFR), US FDA adverse event reporting system (FAERS), paronychia, pharmacovigilance
| Drs Sun and Mao contributed equally to this article. |
|
| Funding sources: National Key R&D Program of China ( 2023YFC2306800 ); Ningbo Natural Science Foundation (Project ID 2023J195 ). |
|
| IRB approval status: Not applicable. |
© 2026
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 95 - N° 1
P. 257-260 - juillet 2026 Retour au numéro
Article précédent
- Simple preventative skin care regimen helps patients undergoing targeted CNS or PNS therapy: A multicenter single-arm trial
- Danny Linggonegoro, Rebecca Levy, Tara McKeown, Julissa Jimenez, Erin McDonough, Madeline Hlobik, Lindsay McCormack, Hannah Song, Susan N. Chi, Nicole J. Ullrich, Wendy B. London, Nan Chen, Karina L. Vivar, Irene Lara-Corrales, Jennifer T. Huang
- Safety outcomes of neuromodulator and dermal filler procedures in a dermatology resident cosmetic clinic
- Kristina Paré, Nathalia Simonetti, Grace McCollam, Leah Jacob, Brittany Stumpf, Andrea Murina
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?